The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anupam Rama - JP Morgan Securities LLC - Analyst
: Thanks, Michael. I just want to remind folks, there's three ways to ask a question, right? There's the old school way where you raise your hand and
I'll call you -- call on you and send the question in the question portal and I read it or I just e-mail it to me, and I'll ask on your behalf.
Michael, maybe I'll just kick off here with, you mentioned, for Revuforj, you mentioned IDH inhibitors. How are you thinking about any analogs that
you might comp this launch to that we should be considering?
Question: Anupam Rama - JP Morgan Securities LLC - Analyst
: And look, I know it's only been a couple of weeks since launch and you said you'll give us a lot more detail on the 4Q call. But just wondering, any
initial learnings from anecdotally from the early innings of launch.
Question: Anupam Rama - JP Morgan Securities LLC - Analyst
: Questions from the audience?
Unidentified Participant
Yeah. So could you maybe speak to a little bit of what you're seeing in terms of how I think the first mover in KMT2A is -- if it's happening, if it's
making doctors more comfortable in terms of how they're viewing the drug in NPM1.
Question: Anupam Rama - JP Morgan Securities LLC - Analyst
: Questions from the audience? Yeah, Alana.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 14, 2025 / 6:30PM, SNDX.OQ - Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference
Unidentified Participant
Can you talk about how you're seeing that your GVHD drug will be used? I mean, because there's multiple drugs in that space. And the question
is, do you start -- even though you start in third line, will there be alternatives? Or what is your understanding on that?
Question: Anupam Rama - JP Morgan Securities LLC - Analyst
: We have an e-mail question here. Michael, are there a bolus of patients from previous Revuforj trials, expanded access or current clinical trial patients
that can that may be transitioning to commercial therapy?
Question: Anupam Rama - JP Morgan Securities LLC - Analyst
: And maybe other one for me.
Question: Anupam Rama - JP Morgan Securities LLC - Analyst
: Kind of post-ASH, there's been a lot of talk about sort of the competitive landscape in menin. Can you speak to why first to market matters in acute
leukemia?
Question: Anupam Rama - JP Morgan Securities LLC - Analyst
: Just maybe just a quick one on Niktimvo. What are the final sort of gating factors to commercializing and getting to market and one. It's early one.
Question: Anupam Rama - JP Morgan Securities LLC - Analyst
: Any final questions from the audience? Alright. Thank you, Michael.
| 
